SEC Form 10-Q filed by Sensei Biotherapeutics Inc.
$SNSE
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $5.00 | Buy | H.C. Wainwright |
| 5/14/2024 | $5.00 | Overweight | Stephens |
| 3/10/2022 | $12.00 → $10.00 | Overweight | Piper Sandler |
| 7/1/2021 | $12.00 | Buy → Hold | Berenberg |
| 6/29/2021 | $30.00 → $14.00 | Outperform → Perform | Oppenheimer |
| 6/29/2021 | Outperform → Perform | Oppenheimer |
10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide
H.C. Wainwright resumed coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $5.00
Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00
Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA candidate and initiate IND-enabling studies by year-end 2021 - SNS-401-NG on track to start IND-enabling studies in second half of 2022 – -Strong cash position of $162.5 million to support platform innovation and next generation program development - BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reporte
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company's development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other op
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors has determined, after extensive consideration of the Company's development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the Compan
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dose cohort –Data support advancement to Phase 2 studies, currently being planned in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma –Sensei to host investor webcast Monday, October 20th at 8:00 AM ET – BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc.
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)